Juniper Biomedical, a medical device company specializing in pelvic health disorders treatment, has successfully completed an oversubscribed $2 million Series Seed financing round. Additionally, the company has been awarded $1 million through the NIH Common Fund as a winner of the NIH SPARC Neuromod Prize. This prestigious competition is designed to accelerate the development of targeted neuromodulation therapies. The funding, led by Auroral Holdings, a MedTech-focused family office, with participation from Atma Capital, Hub Angels, Beacon Angels, and other private investors, signifies a significant milestone for Juniper Biomedical.

With these financial resources, Juniper Biomedical is poised to advance its innovative approach to treating pelvic health disorders. Their primary focus lies in developing solutions that address conditions such as urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders. Led by CEO David Constantine, the company is committed to leveraging its unique neuromodulation micro-implant technology to provide long-term therapy options for patients, particularly those suffering from mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.

David Constantine, expressing his gratitude for the support received, stated, “We are thrilled to have the support and confidence of our investors and NIH as we embark on the next phase of our journey to offer patients better care options.” He emphasized the company’s dedication to utilizing the newly acquired funds to accelerate the development of transformative solutions in the field of pelvic health.

Juniper Biomedical’s recent achievements include significant progress in both preclinical and clinical milestones, indicating strong momentum and growth potential. The infusion of capital will enable the company to complete various development and commercialization milestones for their platform neuromodulation technology. Moreover, it will facilitate the expansion of Juniper Biomedical’s presence in the ecosystem, ensuring the delivery of innovative neuromodulation solutions to underserved patient populations.

Larry Derose, the founder of Auroral Holdings, expressed his confidence in Juniper Biomedical’s potential for growth and disruption in pelvic health treatment. He stated, “We believe that Juniper Biomedical has tremendous potential for growth and disruption in pelvic health in the historically underserved patient populations.” Auroral Holdings is excited to partner with Juniper Biomedical and looks forward to supporting the team’s vision and innovation.

In conclusion, Juniper Biomedical is at the forefront of revolutionizing the treatment landscape for pelvic health disorders. Through its precision-focused approach and innovative technology, the company aims to provide effective, long-term solutions for millions of individuals suffering from these debilitating conditions. With the support of investors and recognition from prestigious organizations like the NIH, Juniper Biomedical is well-positioned to make significant strides in improving patient care and quality of life.